Video Insights
Video Insights
Advertisement
Melissa BadamoMyelodysplastic Syndromes | November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
Melissa BadamoMyelodysplastic Syndromes | November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
Advertisement
Jamile Shammo, MDMyelodysplastic Syndromes | November 15, 2024
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
Melissa BadamoMyelodysplastic Syndromes | November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
Melissa BadamoMyelodysplastic Syndromes | November 1, 2024
More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said.
Jamile Shammo, MDMyelodysplastic Syndromes | October 29, 2024
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
Shebli Atrash, MDMyeloma | October 25, 2024
Dr. Atrash reviews real-world data on four selinexor-based triplets used in the treatment of relapsed or refractory myeloma.
Valeria Santini, MDMyelodysplastic Syndromes | October 24, 2024
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | October 24, 2024
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Jamile Shammo, MDMyelodysplastic Syndromes | October 23, 2024
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
David Swoboda, MDMyelodysplastic Syndromes | October 21, 2024
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
Jamile Shammo, MDMyelodysplastic Syndromes | October 23, 2024
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | November 6, 2024
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
Adriana Rossi, MDMyeloma | October 16, 2024
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
Melissa BadamoT-Cell Lymphoma | October 9, 2024
Stefan K. Barta, MD, MS, discusses his recent study on central nervous system relapse in T-cell lymphomas.
Advertisement
Advertisement
Editorial Board